EUROPEAN JOURNAL OFCANCER
|
|
- Madeline Powers
- 5 years ago
- Views:
Transcription
1 Volume 49, No. 5, March 2013 ISSN EJC EUROPEAN JOURNAL OFCANCER Reprinted from Eur J Cancer. 2013;49(5): BRAF inhibitor activity in V600R metastatic melanoma Oliver Klein, Arthur Clements, Alexander M. Menzies, Sandra O Toole, Richard F. Kefford, Georgina V. Long THE OFFICIAL JOURNAL OF
2 European Journal of of Cancer (2013) (2013) 49, 49, Available at journal homepage: BRAF inhibitor activity in V600R metastatic melanoma Oliver Klein a, Arthur Clements a, Alexander M. Menzies a,b, Sandra O Toole c,d,e,f, Richard F. Kefford a,b,d, Georgina V. Long a,b,d, a Westmead Hospital, Sydney, Australia b Melanoma Institute Australia, Sydney, Australia c Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia d University of Sydney, Sydney, Australia e The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia f St. Vincent s Clinical School, University of New South Wales, Sydney, Australia Available online 10 December 2012 KEYWORDS Metastatic melanoma V600E V600R BRAF inhibitor Vemurafenib Dabrafenib Abstract Activating mutations in the BRAF gene occur in approximately 50% of melanomas. More than 70% of BRAF mutations are V600E and 10 30% are V600K. Potent and selective BRAF inhibitors have demonstrated significant clinical benefits in patients with V600E and V600K BRAF-mutated melanoma. V600R mutations constitute approximately 3 7% of all BRAF mutations and the activity of BRAF inhibitors in patients with this mutation is unknown. We have treated 45 patients with V600 mutated melanoma including patients with V600R mutation between July 2011 and October 2012 with the selective BRAF inhibitor dabrafenib (n = 43) or vemurafenib (n = 2) via a compassionate access programme. The overall response rate was 50% for the whole population with a progression-free survival of 5.5 months. Five objective responses were seen in six assessable patients with V600R BRAF mutation (n = 9). Our experience suggests that patients with V600R BRAF mutations can be treated successfully with oral BRAF inhibitors, and molecular diagnostic assays should include detection of this type of mutation. Ó 2012 Elsevier Ltd. All rights reserved. 1. Introduction Cutaneous melanoma is genetically heterogeneous with subsets defined by specific driver mutations. 1 Corresponding author: Address: Melanoma Institute Australia and Westmead Hospital, University of Sydney, 40 Rocklands Road, North Sydney, New South Wales, Australia. Tel.: ; fax: address: georgina.long@sydney.edu.au (G.V. Long). Approximately 50% of melanomas carry mutations in the BRAF oncogene leading to constitutive activation of the MAP kinase pathway. The majority of BRAF mutations occur in exon 15 of the BRAF gene and 74 95% are due to a V600E amino acid substitution. 2 5 More than 99% of cases of V600E are due to the point mutation c.1799t>a, (Catalogue of Somatic Mutations In Cancer (COSMIC) ID 476). 5 V600K (c.1798_1799gt>aa, COSMIC ID 473), the second most common mutation, /$ - see front matter Ó 2012 Elsevier Ltd. All rights reserved.
3 1074 O. Klein et al. / European Journal of Cancer 49 (2013) occurs in older patients or those with evidence of chronic sun damage at the site of the primary cutaneous melanoma, 6 and comprises 10 30% of the BRAF mutation-positive melanoma population. 2 4 V600R (c.1798_1799gt>ag, COSMIC ID 474) mutations are the third most common mutation occurring in approximately 5 7% of patients with BRAF-mutant melanoma. 7,8 The selective BRAF inhibitors, vemurafenib and dabrafenib, are active in V600E BRAF mutation-positive metastatic melanoma with Response Evaluation Criteria in Solid Tumours (RECIST) 9 response rates of approximately 50% 10 14, a clinical benefit observed in nearly 90% of patients, and a prolonged progression-free and overall survival compared with dacarbazine chemotherapy. 12,14 Activity of dabrafenib has been observed in prospective studies of patients with V600K mutationpositive melanoma 13,15 and retrospective analyses of clinical trials and case series of vemurafenib 11,12,16 but lower response rates and a shorter progression-free survival have been reported in these patients compared with the more common V600E mutation. 15,17 There remains uncertainty as to whether BRAF inhibitors are effective in patients with non-v600e/k mutations. Although there is limited pre-clinical evidence that selective BRAF inhibitors might be active in V600R melanoma, 18 clinical activity has not been reported. This report describes our clinical experience of treating nine patients with V600R mutated metastatic melanoma with dabrafenib (n = 7) or vemurafenib (n = 2) on compassionate access programmes. 2. Patients and methods 2.1. Patient population Between June 2011 and October patients were enroled in a compassionate access programme to receive the selective BRAF inhibitor dabrafenib and an additional two patients with V600R received compassionate vemurafenib. Eligible patients had histologically confirmed metastatic melanoma with a BRAF V600 mutation, were not eligible for an active trial or expanded access programme by the same sponsor, and had an ECOG performance status of three or less. Patients with brain metastases could be enroled if no immediate local treatment was required. Patients received dabrafenib at a dose of 150 mg orally twice daily and the two patients treated with vemurafenib received 960 mg orally twice daily. Radiological disease assessment included computed tomography (CT) scan, and for those with brain metastases at baseline, magnetic resonance imaging (MRI) of the brain with gadolinium enhancement. Assessments were performed at baseline and every 6 10 weeks. Patients were allowed to continue treatment beyond disease progression if there was ongoing clinical benefit as determined by the treating clinician BRAF mutation testing BRAF mutation testing was performed on sections from archival FFPE tissue blocks at 1 of 3 laboratories; Peter MacCallum Cancer Centre, Department of Diagnostic Molecular Pathology (Melbourne, Australia), Royal Prince Alfred Hospital, Department of Clinical and Molecular Genetics (Sydney, Australia) and Healthscope Pathology (Clayton Australia) using one of the following methods. At Peter MacCallum Cancer Centre, samples were macro-dissected and subjected to high resolution melting (HRM) analysis using primers flanking codon 600 in the BRAF gene. These primers identify variations in exon 15 of the BRAF gene between nucleotides c.1788 and c.1823 in reference sequence NM_ , corresponding to codons All abnormal HRM traces were subjected to bidirectional DNA sequencing. At Royal Prince Alfred Hospital, samples were reviewed by a tissue pathologist, macro-dissected to enrich for tumour and the DNA was extracted from formalin fixed paraffin embedded (FFPE) tissue using NucleoSpin FFPE DNA Kit (Macherey Nagel) according to the manufacturer s instruction with an overnight proteinase digestion. The quality and quantity of the extracted DNA was assessed using NanoDrop Ò ND Spectrophotometer. A minimum of 480 ng of DNA was required for successful mutational analysis. Samples were amplified for 238 variant targets in a 24- multiplex polymerase chain reaction (PCR) using the OncoCarta Panel v1.0 Kit (ABL1, AKT1, AKT2, BRAF, CDK, EGFR, ERBB2, FGFR1, FGFR3, FLT3, JAK2, KIT, MET, HRAS, KRAS, NRAS, PDGFR, PIK3CA, RET) and analysed based on the matrix-assisted laser desorption ionisation-time of flight mass spectrometry (MALDI-TOF) technology on the Sequenom MassArray platform. At Healthscope Pathology, haematoxylin and eosinstained sections of FFPE tissue were reviewed by a pathologist, followed by macrodissection to ensure the percentage of tumour cells was enriched to at least 60%. DNA was then extracted using the Qiagen QIAmp mini extraction columns. Exon 15 of the BRAF gene was amplified by PCR. A single-base extension assay was performed using a forward primer that interrogated the nucleotide at position 1798, as well as a reverse primer that interrogated the nucleotide at position The primers were designed using the Sequenom Assay Designer software. Standard protocols based on the Sequenom Typlex kit were then followed according to the manufacturer s instructions. Products of the extension reaction are fired and analysed on a Sequenom Massarray mass spectrometer.
4 O. Klein et al. / European Journal of Cancer 49 (2013) Statistical analysis SPSS software was used to calculate the Kaplan Meier median progression-free survival curve with two-sided 95% confidence interval (CI). 3. Results Between July 2011 and October 2012, 45 patients with BRAF V600 mutated metastatic melanoma received compassionate access to the selective BRAF inhibitors dabrafenib (n = 43) or vemurafenib (n = 2). BRAF mutation genotyping revealed a V600E mutation in 23 (51%), a V600K mutation in 13 (29%) and a V600R mutation in nine (20%) patients (Fig. 1). The majority of patients were male with stage M1c disease, 15 (33%) patients had brain metastases prior to commencement of the BRAF inhibitor, and more than half of all patients had an elevated lactate dehydrogenase (LDH) level (Table 1). Only two patients had received prior systemic therapy with chemotherapy or targeted agents (vemurafenib, trametinib), and none had received ipilimumab. Nine patients of the 45 were not included in the efficacy analysis; three patients deceased prior to the first response assessment and six had not been radiographically assessed for response at the time of reporting. According to the clinician s assessment, the overall response rate was 50% (18/36) for the whole population of assessable patients with 17 patients achieving a partial response and one patient a complete response. The median progression-free survival was 5.5 months (95% CI, ) (Fig. 2). According to the BRAF V600 mutation genotype, 11 of 20 (55%) patients with the V600E mutation, 2 of 10 (20%) with the V600K and 5 of 6 (83%) with the V600R mutation achieved a clinical and radiological response (Fig. 2). Most patients with V600R mutated melanoma (n = 9) were elderly males with a history of an ulcerated primary melanoma (Table 2). One patient, the only female, could be not assessed for response as she deceased due to an intracranial haemorrhage 3 days after commencing dabrafenib, and this was considered Fig. 1. Spectrographs showing the c.1798_1799 GT>AG (V600R) BRAF mutation. The Oncocarta v1.0 assay demonstrates additional mutant peaks at the complementary bases (arrows).
5 1076 O. Klein et al. / European Journal of Cancer 49 (2013) Table 1 Clinical characteristics of patients treated with dabrafenib and vemurafenib. Characteristics Patients (N = 45), n (%) Age, median(range), years 61 (17 84) Sex Male 35 (78) Female 10 (22) BRAF genotype V600E 23 (51) V600K 13 (29) V600R 9 (20) Stage AJCC M1a 1 (2) M1b 4 (9) M1c 40 (89) Brain metastases Present 15 (33) Absent 30 (67) Lactate dehydrogenase Elevated 24 (53) Normal 21 (47) unrelated to dabrafenib. Overall, five of six evaluable patients with V600R mutated melanoma treated with selective BRAF inhibitors achieved a clinical and radiological response (e.g. Figs. 3 and 4). Two additional patients achieved rapid clinical responses shortly after commencing treatment, with a rapid reduction in the size of subcutaneous metastases in both patients, and resolution of neurological symptoms (left hemiparesis power 1/5 to 4/5) in one. Both patients are awaiting their first radiological assessment. Given the lack of knowledge about the clinical efficacy of selective BRAF inhibitors in patients with V600R mutated metastatic melanoma, we describe the clinical course of two patients in more detail Case 1 A 74-year-old man presented with an acute onset of severe headaches and a brain CT scan revealed three haemorrhagic tumours involving the right frontal and parietal lobes. Two of the tumours were resected and histological assessment confirmed metastatic melanoma. Further imaging revealed multiple lung metastases (Fig. 3C). The patient had no history of a primary cutaneous melanoma and skin lesions suspicious of melanoma could not be identified at the time of diagnosis. A V600R mutation in exon 15 of the BRAF gene was detected in the tumour sample and he was subsequently commenced with the BRAF inhibitor dabrafenib after enrolment onto the compassionate access programme. A progress CT scan, 8 weeks after commencement of treatment, confirmed a partial response with a significant decrease in size of the pulmonary metastases and stable intracranial disease. Progress imaging at 16 and 24 weeks (Fig. 3D) after commencement of dabrafenib, revealed an ongoing response with a further decrease in the size of the pulmonary metastases and stable intracranial disease. Ten months after commencing treatment, he progressed with multiple new brain metastases and an increase in size of the pre-existing pulmonary metastases. Subsequently, he has undergone whole brain radiotherapy and continues on dabrafenib. The patient is alive 12 months after commencing drug. A B 1.0 Overall response 0.8 Proportion Progression-free PFS=5.5 months (95% CI, ) Months Fig. 2. Overall response rates (A) and Kaplan Meier progression-free survival analysis (B) of patients with V600 mutated melanoma treated with dabrafenib and vemurafenib.
6 O. Klein et al. / European Journal of Cancer 49 (2013) Case 2 Table 2 Characteristics and treatment responses of patients with V600R BRAF-mutated. Overall survival a Progressionfree survival Best response BRAF inhibitor (BRAFi) Lactate dehydrogenase (LDH) Brain metastases Ulceration Stage AJCC Patient Age Gender Site of primary melanoma 1 75 Male Unknown N/A M1c + Normal Dabrafenib PR 10.4 Alive 2 73 Male Upper limb M1c Elevated Dabrafenib PD Male Scalp + M1b Normal Dabrafenib PR 3.5 Alive 4 54 Male Upper limb + M1c + Normal Dabrafenib PR 3.7+ Alive 5 61 Male Trunk + M1a Elevated Dabrafenib PR 3.2+ Alive 6 64 Male Scalp M1c + Normal Dabrafenib b b Alive 7 63 Female Upper limb + M1c + Normal Dabrafenib c c c 8 81 Male Scalp + M1c Elevated Vemurafenib PR Male Scalp + M1a + Normal Vemurafenib b b Alive AJCC: American Joint Committee on Cancer; PR: partial remission; PD: progressive disease. a Time from commencing BRAF inhibitor. b Clinical response, no radiological assessment performed yet. c Patient deceased few days after commencing treatment. An 81-year-old man was diagnosed with a 3.6 mm, ulcerated primary cutaneous melanoma of the occiput and was treated with wide local excision in March Within 6 months the melanoma recurred at the occiput and the left neck. Both recurrences were resected, including a neck dissection which was followed by radiotherapy. Eight months later in May 2011 disease recurred in the contralateral neck and was treated similarly. Within 4 months extensive unresectable subcutaneous melanoma metastases developed involving the scalp and bilateral peri-auricular regions (Fig. 4A). The patient required regular opiate analgesia, and had exhausted local therapies for disease control at the scalp. A staging CT scan showed an additional 7 mm metastasis in the right lung and a 9 mm metastasis in the liver. Testing of a left neck nodal metastasis revealed a V600R mutation in BRAF exon 15. He was commenced on vemurafenib via compassionate use access, had a marked reduction in the size of the subcutaneous lesions within 1 week, and ceased opiate analgesia. Staging at week 8 showed a RECIST 9 partial response (75%) with a marked reduction of the scalp disease (Fig. 4B). The patient progressed in the scalp 19 weeks after commencing vemurafenib, with continued response in the lung and liver. He ceased vemurafenib at 22 weeks and commenced lenvatinib (E7080) and achieved a partial response. The patient died 9.5 months after commencing vemurafenib due to complications from chronic obstructive pulmonary disease. 4. Discussion Vemurafenib was co-developed clinically with the cobas Ò 4800 BRAF V600 diagnostic test, 19 which while highly sensitive and specific for the exon T>A BRAF gene mutation (V600E), lacks similar sensitivity for non-v600e BRAF mutations. 20 Dabrafenib was prospectively tested in patients with a range of BRAF mutations including V600K and K601E. 13,21 No clinical trials of either drug have included patients with V600R BRAF mutation-positive melanoma, the third most common BRAF mutation. 7 Over a period of 15 months we treated 45 patients with V600 BRAF-mutated metastatic melanoma via compassionate access to the selective BRAF inhibitor dabrafenib or vemurafenib (not the expanded access programme). These patients were not eligible for clinical trials and the population was therefore enriched for patients with non-v600e mutations. The observed overall response rate and the progression-free survival in our patient population is in keeping with the outcome previously reported in clinical trials of BRAF inhibitors In this dataset, there appeared to be a lower response
7 1078 O. Klein et al. / European Journal of Cancer 49 (2013) Fig. 3. Chest computed tomography (CT) scan of patients with metastatic V600R mutated melanoma. (A) Bulky axillary lymph nodes at baseline (top) and week 8 (bottom) after treatment with dabrafenib. (B) Lung metastases at baseline (top) and week 16 (bottom) after treatment with dabrafenib. Circles and arrows indicate areas of response. Fig. 4. Subcutaneous scalp metastases of a patient with V600R mutated melanoma at baseline (A) and at week 8 (B) after treatment with vemurafenib. rate in patients with V600K mutated melanoma as previously demonstrated in clinical trials. 15,17 Our screening experience for BRAF mutations in patients with metastatic melanoma confirms that V600R mutations are the third most common BRAF mutation in keeping with data published in the United States and European population. 7,8 We have previously demonstrated specific clinicopathological features associated with V600K mutation-positive metastatic melanoma. 6 The V600R genotype is common in males and those with ulcerated primary melanomas, and like patients with V600K melanoma, it is common in older
8 O. Klein et al. / European Journal of Cancer 49 (2013) individuals. These observations require confirmation in a larger cohort of patients with V600R mutated melanoma. Five of six evaluable patients with V600R BRAFmutant metastatic melanoma reported here achieved a partial response by RECIST criteria, including a reduction in the size of lung metastases, liver metastases, stabilisation of brain metastases and a marked reduction in subcutaneous metastases to the scalp due to treatment with a BRAF inhibitor. All nine patients had improved symptoms and performance status within days of commencing treatment, including a patient who had RECIST progression by week 8. Two patients are awaiting radiological confirmation of the clinical response and reduction in subcutaneous metastases observed within the first 2 weeks of treatment. The two patients with the longest follow up had durable responses with one progressing in isolated areas at 19 weeks and the other after 44 weeks of therapy. The rapid clinical responses of patients with V600R BRAF mutation-positive melanoma mirror those observed in patients with V600E and V600K mutations, indicating that selective BRAF inhibitors are active against melanoma with this genotype. Our observations suggest that diagnostic BRAF mutation analysis of metastatic melanoma should test for the rarer non-v600e mutations, in addition to V600E. The clinical benefit of BRAF inhibitors in this subset of patients should be formally elucidated in clinical trials, including trials of combined therapies. Our experience demonstrates that patients with V600R mutation-positive metastatic melanoma can be treated effectively with the BRAF inhibitors vemurafenib and dabrafenib. Conflict of interest statement G.V.L. has received honoraria from Roche for lectures; consultancy fees for advisory board membership and support for congress attendance from Glaxo- SmithKline and Roche. The Melanoma Institute Australia received educational grants from Roche. R.F.K. has received institutional reimbursement for Advisory Board membership and support for travel from GlaxoSmithKline, and institutional reimbursement for lectures and Advisory Board membership from Roche. S.A.O T has consultancy fees for advisory board membership and support for conference attendance from Roche. A.M.M. received travel support for conference attendance from Roche and GSK. References 1. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 2012;12: Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29: Jakob JA, Bassett Jr RL, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2011;118: Thomas NE, Edmiston SN, Alexander A, et al. Number of nevi and early-life ambient UV exposure are associated with BRAFmutant melanoma. Cancer Epidemiol Biomarkers Prev 2007;16: Catalogue of Somatic Mutations in Cancer (COSMIC) Website. Wellcome Trust Sanger Institute. Available from: 6. Menzies AM, Haydu LE, Visintin L, et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012;18: Lovly CM, Dahlman KB, Fohn LE, et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One 2012;7:e Houben R, Becker JC, Kappel A, et al. Constitutive activation of the Ras Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 2004;3:6. 9. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45: Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363: Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600- mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366: Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364: Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012;379: Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAFmutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380: Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB) a multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13: Rubinstein JC, Sznol M, Pavlick AC, et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 2010;8: Trefzer U, Minor D, Ribas A, et al. BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK in patients with BRAF mutation-positive (V600E/K) metastatic melanoma Society of Melanoma Research Congress. Pigment Cell Melanoma Res 2011; Yang H, Higgins B, Kolinsky K, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010;70: Cheng S, Koch WH, Wu L. Co-development of a companion diagnostic for targeted cancer therapy. N Biotechnol 2012;29: Halait H, Demartin K, Shah S, et al. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagn Mol Pathol 2012;21: Smalley KS, Aplin AE, Flaherty KT, et al. Meeting report from the 2011 International Melanoma Congress, Tampa, Florida. Pigment Cell Melanoma Res 2012;25:E1 E11.
9 2012 Elsevier Ltd. All rights reserved. No responsibility is assumed by Elsevier, its licensors or associates for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Edited for: Elsevier España, S.L.U. (A member of Elsevier) Av. Josep Tarradellas, Barcelona Tel.: Fax:
Outcomes of Patients With Metastatic Melanoma Treated With Immunotherapy Prior to or After BRAF Inhibitors
Outcomes of Patients With Metastatic Melanoma Treated With Immunotherapy Prior to or After BRAF Inhibitors Allison Ackerman, MD, PhD 1 ; Oliver Klein, MD 2 ; David F. McDermott, MD 1 ; Wei Wang, PhD 3
More informationBRAF Gene Mutation Testing To Select Melanoma Patients for BRAF Inhibitor Targeted Therapy. Original Policy Date
MP 2.04.66 BRAF Gene Mutation Testing To Select Melanoma Patients for BRAF Inhibitor Targeted Therapy Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date
More informationCase Report Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation
Case Reports in Oncological Medicine Volume 2016, Article ID 2672671, 4 pages http://dx.doi.org/10.1155/2016/2672671 Case Report Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic
More informationa study of 754 cases highlighting potential pitfalls and guidelines for
Histopathology 2016 DOI: 10.1111/his.12992 BRAF V600E and NRAS Q61L/Q61R mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines
More informationCorporate Medical Policy
Corporate Medical Policy BRAF Gene Mutation Testing to Select Melanoma or Glioma Patients File Name: Origination: Last CAP Review: Next CAP Review: Last Review: braf_gene_mutation_testing_to_select_melanoma_or_glioma_patients_for_targeted_
More informationEXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%)
Dr Kate Goodhealth Goodhealth Medical Clinic 123 Address Road SUBURBTOWN NSW 2000 Melanie Citizen Referring Doctor Your ref Address Dr John Medico 123 Main Street, SUBURBTOWN NSW 2000 Phone 02 9999 9999
More informationBRAF Gene Mutation Testing to Select Melanoma Patients for BRAF Inhibitor Targeted Therapy
Section: Medicine Effective Date: January 15, 2015 Subsection: Laboratory/Pathology Original Policy Date: March 9, 2012 Subject: BRAF Gene Mutation Testing to Select Melanoma Last Review Status/Date: December
More informationConflict of Interest Disclosure
"NRAS mutation status in advanced melanoma: how much does this really matter to prognosis and therapy?" John Jakob, MD, PhD Department of Melanoma Medical Oncology, The University of Texas M.D. Anderson
More informationCorporate Medical Policy
Corporate Medical Policy BRAF Gene Variant Testing to Select Melanoma or Glioma Patients File Name: Origination: Last CAP Review: Next CAP Review: Last Review: braf_gene_variant_testing_to_select_melanoma_or_glioma_patients_for_targeted_
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationEfficacy of anti-pd-1 therapy in patients with melanoma brain metastases
Efficacy of anti-pd-1 therapy in patients with melanoma brain metastases John J. Park 1, Sagun Parakh 2,3,4, Shehara Mendis 5, Rajat Rai 6, Wen Xu 7, Serigne Lo 6, Martin Drummond 6, Catherine Rowe 7,
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationNormal RAS-RAF (MAPK) pathway signaling
BRAF-Mutations in Melanomas L. Mazzucchelli Istituto Cantonale di Patologia, Locarno 77. Annual Meeting Swiss Society of Pathology, Lucerne 2011 Sponsored by Roche Pharma Switzerland Melanoma has increased
More informationLocally Advanced and Metastatic Melanoma. Relevant disclosures 6/23/2018. What is the median survival of metastatic melanoma? Abel D.
Locally Advanced and Metastatic Melanoma Abel D. Jarell, MD, FAAD Adjunct Dartmouth School of Medicine, Hanover, NH Northeast Dermatology Associates, Portsmouth, NH Relevant disclosures What is the median
More informationBRAF/MEK inhibitors in the systemic treatment of advanced skin melanoma
QUALITY OF LIFE IN ONCOLOGY Review article BRAF/MEK inhibitors in the systemic treatment of advanced skin melanoma Maksymilian Kruczała, Aleksandra Grela-Wojewoda, Marek Ziobro Clinic of Systemic and Metastatic
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic BRAF V600 mutation-positive melanoma mutation-positive melanoma
More informationBRAF Genetic Testing to Select Melanoma or Glioma Patients for Targeted Therapy
Medical Policy Manual Genetic Testing, Policy No. 41 BRAF Genetic Testing to Select Melanoma or Glioma Patients for Targeted Therapy Next Review: August 2019 Last Review: July 2018 Effective: August 1,
More informationDiscordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy
480 & 2015 USCAP, Inc All rights reserved 0893-3952/15 $32.00 Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy Joshua R Bradish 1,4,
More informationThe Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma
The Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma Reinhard Dummer, 1 Keith Flaherty, 2 Richard Kefford, 3 Paolo A. Ascierto, 4 Laure Moutouh-de Parseval,
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Vemurafenib (Zelboraf) for Advanced Melanoma October 1, 2012
pan-canadian Oncology Drug Review Final Clinical Guidance Report Vemurafenib (Zelboraf) for Advanced Melanoma October 1, 2012 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationCombiRT in Metastatic Melanoma Trial
CombiRT in Metastatic Melanoma Trial An open-label, single-arm, phase I/II, multicenter study to evaluate the safety and efficacy of the combination of dabrafenib, trametinib and palliative radiotherapy
More informationPersonalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients
Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs
More informationResponse and resistance to BRAF inhibitors in melanoma
Response and resistance to BRAF inhibitors in melanoma Keith T. Flaherty, M.D. Massachusetts General Hospital Cancer Center Disclosures Roche/Genentech: consultant GlaxoSmithKline: consultant BRAF mutations
More informationTemplate for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma Template web posting date: February 2015 Authors Lynette M. Sholl, MD, FCAP* Department of Pathology, Brigham
More informationMetastasectomy for Melanoma What s the Evidence and When Do We Stop?
Metastasectomy for Melanoma What s the Evidence and When Do We Stop? Vernon K. Sondak, M D Chair, Moffitt Cancer Center Tampa, Florida Focus on Melanoma London, UK October 15, 2013 Disclosures Dr. Sondak
More informationDabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
CCR Drug Updates Clinical Cancer Research Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma Alexander M. Menzies and Georgina V. Long Abstract Dabrafenib and trametinib
More informationJ Clin Oncol 34: by American Society of Clinical Oncology INTRODUCTION
VOLUME 34 NUMBER 8 MARCH 10, 2016 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Overall Survival and Durable Responses in Patients With BRAF V600 Mutant Metastatic Melanoma Receiving Dabrafenib
More informationSummary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 Long-term results show adjuvant therapy with ipilimumab improves OS in high
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationBRAF Mutation Analysis
Last Review Date: October 13, 2017 Number: MG.MM.LA.38aC Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK
More informationTargeted Therapies in Melanoma
Mutations and Targets Targeted Therapies in Melanoma ckit NRAS
More informationNCCN Guidelines for Cutaneous Melanoma V Meeting on 06/20/18
ME-1, ME-3, ME-B Submission from Castle Biosciences, Inc (05/30/18) to consider inclusion of the DecisionDx-Melanoma test in the guidelines as a prognostic test that provides stratification according to
More informationBRAF Inhibitors in Metastatic disease. Grant McArthur MB BS PhD Peter MacCallum Cancer Centre Melbourne, Australia
Inhibitors in Metastatic disease Grant McArthur MB BS PhD Peter MacCallum Cancer Centre Melbourne, Australia Disclosures Research Support Pfizer & Cellgene Consultant Provectus Mortality from Melanoma
More informationBlack is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove)
Black is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove) Provincial Cancer Care Conference 2018 Ralph P.W. Wong MD FRCPC St Boniface Site Director
More informationINIBITORE di BRAF nel MELANOMA
INIBITORE di BRAF nel MELANOMA Paola Agnese Cassandrini Negrar,29 novembre 2016 BRAF is a serine/threonine protein kinasi encoded on chromosome 7q34 that activates the MAP kinase/erksegnaling pathway
More informationVemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study
Annals of Oncology 28: 634 641, 2017 doi:10.1093/annonc/mdw641 Published online 19 December 2016 ORIGINAL ARTICLE Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm,
More informationpresentation session & clinical Keith T. Flaherty, M.D. Abramson Cancer Center of the University of Pennsylvania
Melanoma: highlights from the oral presentation session & clinical science symposium at ASCO 2009 Keith T. Flaherty, M.D. Abramson Cancer Center of the University of Pennsylvania Abstracts to be discussed
More informationDr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital. NSW Health Pathology University of Sydney
Dr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital NSW Health Pathology University of Sydney Thyroid Cancer TC incidence rates in NSW Several subtypes - Papillary
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationCollaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation
Collaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation Dr Jenni Fairley Deputy Scheme Director (Molecular Pathology), GenQA, Edinburgh, UK From 1 st
More informationBRAF Inhibition in Melanoma
BRAF Inhibition in Melanoma New York City, Mar 22-23, 2013 Bartosz Chmielowski, MD, PhD Assistant Clinical Professor University of California Los Angeles Disclosures Speaker Bureau: BMS, Genentech, Prometheus
More informationUniversity of California Los Angeles, Los Angeles, CA; 2. Department of Dermatology, University of Kiel, Kiel, Germany;
Final Efficacy Results of A3671009, a Phase III Study of Tremelimumab vs Chemotherapy (Dacarbazine or Temozolomide) in First-line Patients With Unresectable Melanoma Antoni Ribas, 1 Axel Hauschild, 2 Richard
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationBest Practices in the Treatment and Management of Metastatic Melanoma. Melanoma
Best Practices in the Treatment and Management of Metastatic Melanoma Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology Assistant
More informationMELANOMA: THE BEST OF THE YEAR Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone
MELANOMA: THE BEST OF THE YEAR 2018 Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone The Best of the Year 2018: MELANOMA CHIRURGIA TERAPIA ADIUVANTE TERAPIA PER MALATTIA AVANZATA The Best of the Year
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationFrequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R
Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Malignant Melanoma
Nth of Scotland Cancer Netwk Clinical Management Guideline f Malignant Melanoma Based on WOSCAN CMG with further consultation within NOSCAN UNCONTROLLED WHEN PRINTED Prepared by Approved by Issue date
More informationCirculating Tumor DNA in GIST and its Implications on Treatment
Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Malignant melanoma: assessment and management of malignant melanoma 1.1 Short title Malignant Melanoma 2 The remit The Department
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationUpdate on Genetic Testing for Melanoma
Update on Genetic Testing for Melanoma Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine Hospital of the University of Pennsylvania February 18, 2018 AAD
More informationImmunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationIdentification of BRAF mutations in melanoma lesions with the Roche z480 instrument
Identification of BRAF mutations in melanoma lesions with the Roche z480 instrument Márta Széll IAP, Siófok May 14, 2012 Multifactorial skin diseses: much more frequent then genodermatoses exhibit familial
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationTreatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC
Treatment and management of advanced melanoma: 2018 Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Disclosure Paul B. Chapman, MD Nothing to disclose. Off
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationBRAF inhibitors in advanced BRAF-positive non-small cell lung cancer
Editorial BRAF inhibitors in advanced BRAF-positive non-small cell lung cancer Tiziana Vavalà Department of Oncology, ASL CN1, Hospital of Saluzzo, 58 Spielberg street, 12037 Saluzzo (CN), Italy Correspondence
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationInnovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD
Innovations in Immunotherapy - Melanoma Systemic Therapies October 27, 2018 Charles L. Bane, MD Melanoma Prognosis Survival at 10 years Stage I: 90% Stage II: 60% Stage III: 40% Stage IV: 10% 2 Indications
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationRare melanoma: Are the options improving? Dr Neil Steven Consultant in Medical Oncology University Hospital Birmingham University of Birmingham
Rare melanoma: Are the options improving? Dr Neil Steven Consultant in Medical Oncology University Hospital Birmingham University of Birmingham Classifying melanoma Melanoma (site of origin, thickness,
More informationBRAFp.V600E, p.v600k, and p.v600r Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?
RESEARCH ARTICLE BRAFp.V600E, p.v600k, and p.v600r Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features? Giovanni Ponti, MD, PhD,* Aldo Tomasi, MD,*
More informationNew Targeted Therapies in Melanoma
Vemurafenib and ipilimumab have improved overall survival in patients with metastatic melanoma. Tenzin Norbu Lama. Returning Home (detail). New Targeted Therapies in Melanoma Ragini R. Kudchadkar, MD,
More informationWHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example
WHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example YIDOU ZHANG Health Economics and Payer Analytics Director Oncology Payer Evidence and Pricing, AstraZeneca
More informationDiagnostics consultation document KRAS mutation testing of tumours in adults with metastatic colorectal cancer
National Institute for Health and Care Excellence Diagnostics consultation document KRAS mutation testing of tumours in adults with The National Institute for Health and Care Excellence (NICE) is producing
More informationResponse and resistance in melanoma. Helen Rizos
Response and resistance in melanoma Helen Rizos RESISTANCE: Kinase inhibitors PI3K only 5% MAPK+PI3K 20% Unknown 38% MAPK 37% BRAF amplification 15% 111 pati ents 100 BRA F inhibitor 11 BRAF+MEK inhibitor
More informationvemurafenib 240mg film-coated tablet (Zelboraf ) SMC No. (792/12) Roche Products Ltd.
Resubmission vemurafenib 240mg film-coated tablet (Zelboraf ) SMC No. (792/12) Roche Products Ltd. 08 November 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationBRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy
BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy Diana Meckbach 1, Ulrike Keim 1, Sabina Richter 1, Ulrike Leiter 1, Thomas K Eigentler 1,Jürgen
More informationThe discovery of targetable driver mutations in a subset of
Original Article Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers Anya M. Litvak, MD,* Paul K. Paik, MD,* Kaitlin M. Woo, MS, Camelia S. Sima, MD, Matthew D. Hellmann, MD,*
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Trametinib (Mekinist) for Metastatic Melanoma October 22, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Trametinib (Mekinist) for Metastatic Melanoma October 22, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationCME/SAM. Molecular Diagnostics of Melanoma Fine-Needle Aspirates. A Cytology-Histology Correlation Study
Anatomic Pathology / Molecular Diagnostics of Melanoma FNAs Molecular Diagnostics of Melanoma Fine-Needle Aspirates A Cytology-Histology Correlation Study Kurt D. Bernacki, MD, 1* Bryan L. Betz, PhD, 1*
More informationFEP Medical Policy Manual
FEP Medical Policy Manual FEP 2.04.77 BRAF Gene Mutation Testing to Select Melanoma or Glioma Patients for Targeted Effective Date: October 15, 2017 Related Policies: None BRAF Gene Mutation Testing to
More informationMelanoma BRAF mutado y terapias dirigidas. Javier Medina Martínez Hospital Virgen de la Salud, Toledo
Melanoma BRAF mutado y terapias dirigidas Javier Medina Martínez Hospital Virgen de la Salud, Toledo Enfermedad avanzada: Seguimiento a largo plazo Retratamiento Metástasis cerebrales Adyuvancia November-2017
More informationUpdate on Targeted Therapy in Melanoma
Update on Targeted Therapy in Melanoma Seville June 2013 James Larkin FRCP PhD London UK Overview What are the targets in melanoma? BRAF / KIT / NRAS / GNAQ / MEK DNA / microtubules CTLA4 / PD1 / PDL1
More informationGenetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology
Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Outline Germline testing CDKN2A BRCA2 BAP1 Somatic testing Gene expression profiling (GEP) BRAF Germline vs Somatic testing
More informationThe absence of the ERBB4 hotspot mutations in melanomas in patients from southern China
Brief Report The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China Qi-Ming Zhou 1,2,5*, Wei Li 6*, Yuan-Xiang Guan 1,3, Xing Zhang 1,2, Xin-Chun Chen 6, Ya Ding 1,2, Xi-Zhi
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationDr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory
Dr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory Personalised Therapy/Precision Medicine Selection of a therapeutic drug based on the presence or absence of a specific
More informationSupplementary Online Content
Supplementary Online Content Venook AP, Niedzwiecki D, Lenz H-J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced
More informationPersonalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader
Personalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader Agenda PHC Approach Provides Better Patient Outcome FMI offers Comprehensive Genomic Profiling,
More informationNext generation diagnostics Bringing high-throughput sequencing into clinical application
Next generation diagnostics Bringing high-throughput sequencing into clinical application Leonardo A. Meza-Zepeda, PhD Translational Genomics Group Institute for Cancer Research Leonardo.Meza-Zepeda@rr-research.no
More informationBRAF Targeted Therapy for Patients with Melanoma and Active Brain Metastases: A Review of Clinical Effectiveness
CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL BRAF Targeted Therapy for Patients with Melanoma and Active Brain Metastases: A Review of Clinical Effectiveness Service Line: Rapid Response
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationInfluence of ERCC2 gene polymorphisms on the treatment outcome of osteosarcoma
Influence of ERCC2 gene polymorphisms on the treatment outcome of osteosarcoma Z.F. Liu, A.L.J. Asila, K. Aikenmu, J. Zhao, Q.C. Meng and R. Fang Department of Orthopaedics, Chinese Medicine Hospital of
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
KRAS, NRAS, and BRAF Variant Analysis in Metastatic Colorectal Cancer Page 1 of 25 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: KRAS, NRAS, and BRAF Variant Analysis
More informationCombination Approaches in Melanoma: A Balancing Act
Combination Approaches in Melanoma: A Balancing Act Antoni Ribas, MD, PhD Jonsson Comprehensive Cancer Center University of California Los Angeles Los Angeles, California Advances in the Treatment of Metastatic
More informationMedical Treatment for Melanoma Sanjiv S. Agarwala, MD
Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Disclosures None Overview
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationKIT Inhibition in Advanced Melanoma: Rationale and Clinical i l Results
KIT Inhibition in Advanced Melanoma: Rationale and Clinical i l Results Richard D. Carvajal, M.D. Assistant Attending Physician Melanoma/Sarcoma Service Memorial Sloan-Kettering Cancer Center Disclosures
More informationHow can we reduce the mortality from melanoma in Australia?
How can we reduce the mortality from melanoma in Australia? Professor Grant McArthur MB BS PhD Peter MacCallum Cancer Centre Melbourne, Australia University of Melbourne, Parkville, Australia What is melanoma?
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationpan-canadian Oncology Drug Review Submitter or Manufacturer Feedback on a pcodr Expert Review Committee Initial Recommendation
pan-canadian Oncology Drug Review Submitter or Manufacturer Feedback on a pcodr Expert Review Committee Initial Recommendation Vemurafenib (Zelboraf) for Advanced Melanoma June 1, 2012 3 Feedback on perc
More informationValidated and promising predictive factors in mcrc: Recent updates on RAS testing Fotios Loupakis, MD PhD
Validated and promising predictive factors in mcrc: Recent updates on RAS testing Fotios Loupakis, MD PhD U.O. Oncologia 2 Universitaria Azienda Ospedaliero-Universitaria Pisana Pisa, Italy Learning Objectives
More information